Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Update Il y a 4 ans
Reference: NCT00366340

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal conjugate (Prevenar/Prevenar®, 7vPnC), when given concomitantly with Infanrix hexa at 2, 3, 4, months (infant series) and at 11-12 months of age (toddler dose) in Germany.


Inclusion criteria

  • Vaccines, Pneumococcal

Links